Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In September the commissioner of the FDA resigned, leaving a leadership vacuum and a lack of certainty that is likely to force biotech companies to stick to pharmaceutical alliances rather than going it alone in seeking drug approval.
Neither antibiotech activist nor Dr. Frankenstien, Eduardo Kac is a writer and artist whose theme is that in biotech, as in all science and technology, nothing is as good or as bad as it seems.
Just three months after the results of two innovative and potentially cost-effective sequencing technologies were announced, one instrument has been launched on the market. Does this mean the $1,000 genome may be within sight? Jim Kling investigates.
With a growing need for better and more plentiful vaccines, traditional vaccine companies are responding by increasing manufacturing capacity, the biotech industry, with innovative products. Both are surely needed.